Treatment Adverse Events Vary With Favorable, Unfavorable Prognosis in Prostate Cancer
By Elana Gotkine HealthDay Reporter
MONDAY, Jan. 29, 2024 -- For patients with localized prostate cancer, the rates of adverse outcomes associated with specific treatments vary for favorable- and unfavorable-prognosis disease, according to a study published online in the Jan. 23/30 issue of the Journal of the American Medical Association.
Bashir Al Hussein Al Awamlh, M.D., from Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues conducted an observational cohort study using data from five U.S. Surveillance, Epidemiology, and End Results Program registries to compare rates of adverse functional outcomes between specific treatments for localized prostate cancer. At baseline, 1,877 and 568 participants had favorable- and unfavorable-prognosis prostate cancer. Treatment included radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance for favorable-prognosis disease (1,043, 359, 96, and 379, respectively) and radical prostatectomy or external beam radiotherapy with androgen deprivation therapy for unfavorable-prognosis disease (362 and 206, respectively). Patients were followed for a median of 9.5 years.
The researchers found that compared with active surveillance, radical prostatectomy was associated with worse urinary incontinence but not sexual function among men with a favorable prognosis. Among those with an unfavorable prognosis, radical prostatectomy was associated with worse urinary incontinence but not sexual function compared with external beam radiotherapy with androgen deprivation therapy. Worse bowel and hormone function were seen for those with an unfavorable prognosis receiving external beam radiotherapy with androgen deprivation therapy compared with radical prostatectomy.
"In this observational study of patients with localized prostate cancer followed up for approximately 10 years, functional outcomes varied by treatment and prognosis at the time of diagnosis," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
New Prostate Cancer Urine Test Has High Diagnostic Accuracy
MONDAY, April 22, 2024 -- A new prostate cancer test has higher diagnostic accuracy for high-grade disease than current guideline-endorsed biomarkers, according to a study...
Evidence Lacking for Gender Dysphoria Treatments for Teens
FRIDAY, April 12, 2024 -- Evidence is lacking for use of puberty blockers and hormone treatment for gender dysphoria/incongruence, according to two systematic reviews published...
HYPORT Noninferior for GU, GI Toxicity in Prostate Cancer
WEDNESDAY, April 10, 2024 -- For patients with prostate cancer, hypofractionated postprostatectomy radiotherapy (HYPORT) is noninferior to conventionally fractionated...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.